Glucosamine and Chondroitin Effects

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01682694

Acronym

GLANCE

Enrollment

Registered

2012-09-11

Start date

2012-09-30

Completion date

2013-08-31

Last updated

2014-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammation

Brief summary

A common starting dose of glucosamine and chondroitin will reduce inflammation as reflected by a reduction in serum C-reactive protein.

Detailed description

Use of glucosamine and chondroitin have been associated with reduced cancer and overall mortality. The aim of this study is to determine whether a common starting dose of glucosamine and chondroitin (1500 mg/d + 1200 mg/d, respectively) reduces systemic inflammation as reflected by a reduction in high sensitivity C-reactive protein.

Interventions

DIETARY_SUPPLEMENTGlucosamine and Chondroitin

Glucosamine (1500 mg) and Chondroitin (1200 mg)

DIETARY_SUPPLEMENTplacebo

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

20 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy * Overweight (body mass index kg/m2 (BMI) between 25 and 32.5) * Non-smoking men and women * Aged 20-55y

Exclusion criteria

* Chronic medical illness, history of gastrointestinal, hepatic, or renal disorders, or inflammatory conditions (including autoimmune and inflammatory diseases) * Pregnancy or lactation * Currently on a weight-loss diet * BMI (body mass index) \< 25 or \> 30 * Alcohol intake of greater than 2 drinks/day * Current use of prescription or over-the-counter medications, (Excluding oral contraceptives and hormone-secreting IUDs), including use of aspirin or NSAIDs more than 2 days per week * Abnormal renal, liver or metabolic test * Inability to swallow pills * Known allergy to shellfish * Not willing to take pills made from shellfish or animal sources * Intention to relocate out of study area within next 4 months

Design outcomes

Primary

Measure	Time frame	Description
hsCRP	1 year	hsCRP is a biomarker of systemic inflammation

Secondary

Measure	Time frame	Description
untargeted (exploratory) serum metabolomics (differences in small molecule abundance ratios)	1 year	The mechanisms of action of glucosamine and chondroitin are currently unknown. Untargeted metabolomic assays of serum will be undertaken for exploratory analyses of potential effects of glucosamine and chondroitin. Significant differences in abundance ratios of small molecules between the intervention and placebo will be reported.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 5, 2026